Vitenskapelig artikkel

• Korbmacher, Max; Lie, Ingrid Anne; Wesnes, Kristin et al. (2025). Multimodal predictors of disability progression and processing speed decline in relapsing–remitting multiple sclerosis. (ekstern lenke)
• Hellwig, Kerstin; Magyari, Melinda; MacDonald, Thomas M. et al. (2025). A multi-country cohort database study to assess pregnancy and infant outcomes after potential maternal or paternal exposure to cladribine tablets in the treatment of multiple sclerosis: the CLEAR study methods and status update. (ekstern lenke)
• Rød, Brit Ellen; Høgestøl, Einar August; Torkildsen, Øivind et al. (2025). Comparative effectiveness of rituximab and cladribine in relapsing–remitting multiple sclerosis: A target trial emulation. (ekstern lenke)
• Fossum, Maria Therese; Torgauten, Hilde Marie; Aarseth, Jan Harald et al. (2025). Early extended interval dosing of rituximab in multiple sclerosis: A comparative cohort study on efficacy and safety. (ekstern lenke)
• Nakken, Ola; Aarseth, Jan Harald; Wergeland, Stig et al. (2024). BCG vaccination and multiple sclerosis risk: A Norwegian cohort study. (ekstern lenke)
• Eid, Karine; Torkildsen, Øivind; Aarseth, Jan Harald et al. (2024). Migraine in the multiple sclerosis prodrome: a prospective nationwide cohort study in pregnant women. (ekstern lenke)
• Torgauten, Hilde Marie; Onyango, Therese Bredholt; Ljostveit, Sonja et al. (2024). Hospitalisations and humoral COVID-19 vaccine response in vaccinated rituximab-treated multiple sclerosis patients. (ekstern lenke)
• Hillert, Jan; Butzkueven, Helmut; Magyari, Melinda et al. (2024). Harmonized Data Quality Indicators Maintain Data Quality in Long-Term Safety Studies Using Multiple Sclerosis Registries/Data Sources: Experience from the CLARION Study. (ekstern lenke)
• Butzkueven, Helmut; Hillert, Jan; Soilu-Hänninen, Merja et al. (2023). The CLARION study: first report on safety findings in patients newly initiating treatment with cladribine tablets or fingolimod for multiple sclerosis. (ekstern lenke)
• Kråkenes, Torbjørn; Wergeland, Stig; Al-Sharabi, Niyaz Abdulbaqi Abdulmajid et al. (2023). The neuroprotective potential of mesenchymal stem cells from bone marrow and human exfoliated deciduous teeth in a murine model of demyelination. (ekstern lenke)
• Habbestad, Andrea Kyvik; Willumsen, Johannes Sverre; Aarseth, Jan Harald et al. (2023). Increasing age of multiple sclerosis onset from 1920 to 2022: a population-based study. (ekstern lenke)
• Rød, Brit Ellen; Wergeland, Stig; Bjørnevik, Kjetil Lauvland et al. (2023). Humoral response to Epstein-Barr virus in patients with multiple sclerosis treated with B cell depletion therapy. (ekstern lenke)
• Ahmad, Intakhar; Wergeland, Stig; Oveland, Eystein et al. (2023). An Association of Chitinase-3 Like-Protein-1 With Neuronal Deterioration in Multiple Sclerosis. (ekstern lenke)
• Roar, Malte; Nielsen, Amalie Rhode Høgh; Berg, Jonas Munksgaard et al. (2023). Discontinuation of dimethyl fumarate in multiple sclerosis - a nationwide study. (ekstern lenke)
• Karlowicz, Jakob Rishovd; Klakegg, Mattias; Aarseth, Jan Harald et al. (2023). Predictors of hospitalization due to infection in rituximab-treated MS patients. (ekstern lenke)
• Eid, Karine; Torkildsen, Øivind; Aarseth, Jan Harald et al. (2022). Association of adverse childhood experiences with the development of multiple sclerosis. (ekstern lenke)
• Eid, Karine; Torkildsen, Øivind; Aarseth, Jan Harald et al. (2022). Abuse and revictimization in adulthood in multiple sclerosis: a cross-sectional study during pregnancy. (ekstern lenke)
• Rød, Brit Ellen; Torkildsen, Øivind; Myhr, Kjell-Morten et al. (2022). Safety of breast feeding during rituximab treatment in multiple sclerosis. (ekstern lenke)
• Lie, Ingrid Anne; Wesnes, Kristin; Kvistad, Silje Agnethe Stokke et al. (2022). The Effect of Smoking on Long-term Gray Matter Atrophy and Clinical Disability in Patients with Relapsing-Remitting Multiple Sclerosis. (ekstern lenke)
• Lie, Ingrid Anne; Kacar, Sezgi; Wesnes, Kristin et al. (2022). Serum neurofilament as a predictor of 10-year grey matter atrophy and clinical disability in multiple sclerosis: a longitudinal study. (ekstern lenke)
• Wesnes, Kristin; Myhr, Kjell-Morten; Riise, Trond et al. (2021). Low vitamin D, but not tobacco use or high BMI, is associated with long-term disability progression in multiple sclerosis. (ekstern lenke)
• Eid, Karine; Torkildsen, Øivind Fredvik Grytten; Aarseth, Jan Harald et al. (2021). Perinatal Depression and Anxiety in Women with Multiple Sclerosis: A Population-Based Cohort Study. (ekstern lenke)
• König, Marton; Lorentzen, Åslaug Rudjord; Torgauten, Hilde Marie et al. (2021). Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations. (ekstern lenke)
• Wergeland, Stig; Parkar, Anagha P; Maric, Snezana et al. (2021). En ung kvinne med langvarig kvalme, oppkast og hikke. (ekstern lenke)
• Torgauten, Hilde Marie; Myhr, Kjell-Morten; Wergeland, Stig et al. (2021). Safety and efficacy of rituximab as first- and second line treatment in multiple sclerosis – A cohort study. (ekstern lenke)
• Norborg, Hilde; Riise, Trond; Myhr, Kjell-Morten et al. (2021). Real-world discontinuation rate of teriflunomide and dimethyl fumarate in multiple sclerosis. (ekstern lenke)
• Oveland, Eystein; Ahmad, Intakhar; Lereim, Ragnhild Reehorst et al. (2021). Cuprizone and EAE mouse frontal cortex proteomics revealed proteins altered in multiple sclerosis. (ekstern lenke)
• Ahmad, Intakhar; Wergeland, Stig; Oveland, Eystein et al. (2021). A higher proportion of ermin-immunopositive oligodendrocytes in areas of remyelination. (ekstern lenke)
• Nystad, Agnes Elisabeth; Lereim, Ragnhild Reehorst; Wergeland, Stig et al. (2019). Fingolimod downregulates brain sphingosine-1-phosphate receptor 1 levels but does not promote remyelination or neuroprotection in the cuprizone model. (ekstern lenke)
• Stokke, Silje Agnethe; Myhr, Kjell-Morten; Holmøy, Trygve et al. (2018). Serum levels of leptin and adiponectin are not associated with disease activity or treatment response in multiple sclerosis. (ekstern lenke)
• Nystad, Agnes Elisabeth; Torkildsen, Øivind; Wergeland, Stig (2018). Effects of vitamin D on axonal damage during de- and remyelination in the cuprizone model. (ekstern lenke)
• Bjørnevik, Kjetil Lauvland; Myhr, Kjell-Morten; Beiske, Antonie Giæver et al. (2018). α-Linolenic acid is associated with MRI activity in a prospective cohort of multiple sclerosis patients.. (ekstern lenke)
• Varhaug, Kristin Nielsen; Barro, Christian; Bjørnevik, Kjetil Lauvland et al. (2017). Neurofilament light chain predicts disease activity in relapsing-remitting MS. (ekstern lenke)
• Oveland, Eystein; Nystad, Agnes Elisabeth; Berven, Frode et al. (2017). 1,25-Dihydroxyvitamin-D3 induces brain proteomic changes in cuprizone mice during remyelination involving calcium proteins. (ekstern lenke)
• Lereim, Ragnhild Reehorst; Oveland, Eystein; Xiao, Y. et al. (2016). The Brain Proteome of the Ubiquitin Ligase Peli1 Knock-Out Mouse during Experimental Autoimmune Encephalomyelitis. (ekstern lenke)
• Holmøy, Trygve; Esbensen, Qin Ying; Torkildsen, Øivind et al. (2016). WT1 and interferon-β–vitamin D association in MS: a longitudinal study.. (ekstern lenke)
• Kvistad, Silje; Myhr, Kjell-Morten; Holmøy, Trygve et al. (2016). No association of tobacco use and disease activity in multiple sclerosis. (ekstern lenke)
• Wergeland, Stig; Myhr, Kjell-Morten; Løken-Amsrud, Kristin Ingeleiv et al. (2016). Vitamin D, HLA-DRB1 and Epstein-Barr virus antibody levels in a prospective cohort of multiple sclerosis patients. (ekstern lenke)
• Stokke, Silje Agnethe; Myhr, Kjell-Morten; Holmøy, Trygve et al. (2015). Body mass index influence interferon-beta treatment response in multiple sclerosis. (ekstern lenke)
• Røsjø, Egil Rørvik; Myhr, Kjell-Morten; Løken-Amsrud, Kristin Ingeleiv et al. (2015). Vitamin D status and effect of interferon-β1a treatment on MRI activity and serum inflammation markers in relapsing-remitting multiple sclerosis. (ekstern lenke)
• Fjær, Sveinung; Bø, Lars; Myhr, Kjell-Morten et al. (2015). Magnetization transfer ratio does not correlate to myelin content in the brain in the MOG-EAE mouse model. (ekstern lenke)
• Alme, Maria Nordheim; Nystad, Agnes Elisabeth; Bø, Lars et al. (2015). Fingolimod does not enhance cerebellar remyelination in the cuprizone model. (ekstern lenke)
• Kuhle, Jens; Disanto, G; Dobson, R et al. (2015). Conversion from clinically isolated syndrome to multiple sclerosis: A large multicantre study. (ekstern lenke)
• Nystad, Agnes Elisabeth; Wergeland, Stig; Aksnes, Lage et al. (2014). Effect of high-dose 1.25 dihydroxyvitamin D3 on remyelination in the cuprizone model. (ekstern lenke)
• Torkildsen, Øivind; Myhr, Kjell-Morten; Wergeland, Stig (2014). Treatment-resistant immune thrombocytopenic purpura associated with LDN use in a patient with MS. (ekstern lenke)
• Røsjø, Egil Rørvik; Myhr, Kjell-Morten; Løken-Amsrud, Kristin Ingeleiv et al. (2014). Increasing serum levels of vitamin A, D and E are associated with alterations of different inflammation markers in patients with multiple sclerosis. (ekstern lenke)
• Stokke, Silje Agnethe; Myhr, Kjell-Morten; Holmøy, Trygve et al. (2014). Antibodies to Epstein-Barr virus and MRI disease activity in multiple sclerosis. (ekstern lenke)
• Løken, Kristin Ingeleiv; Myhr, Kjell-Morten; Bakke, Jacob et al. (2013). Retinol levels are associated with magnetic resonance imaging outcomes in multiple sclerosis. (ekstern lenke)
• Torkildsen, Øivind; Løken-Amsrud, Kristin Ingeleiv; Wergeland, Stig et al. (2013). Fat-soluble vitamins as disease modulators in multiple sclerosis. (ekstern lenke)
• Fjær, Sveinung; Bø, Lars; Lundervold, Arvid et al. (2013). Deep gray matter demyelination detected by magnetization transfer ratio in the cuprizone model. (ekstern lenke)
• Løken-Amsrud, Kristin Ingeleiv; Myhr, Kjell-Morten; Bakke, Søren Jacob et al. (2013). Alpha-tocopherol and MRI outcomes in multiple sclerosis - association and prediction. (ekstern lenke)
• Holmøy, Trygve; Løken-Amsrud, Kristin Ingeleiv; Bakke, Jacob et al. (2013). Inflammation markers in multiple sclerosis: CXCL16 reflects and may also predict disease activity. (ekstern lenke)
• Wergeland, Stig; Torkildsen, Øivind; Myhr, Kjell-Morten et al. (2012). The cuprizone model: regional heterogeneity of pathology. (ekstern lenke)
• Torkildsen, Øivind; Wergeland, Stig; Bakke, Jacob et al. (2012). ω-3 fatty acid treatment in multiple sclerosis (OFAMS study): a randomised, double blind, placebo-controlled trial. (ekstern lenke)
• Myhr, Kjell-Morten; Grytten, Nina Agnethe; Torkildsen, Øivind et al. (2012). A need for national registries and international collaborative research in multiple sclerosis. (ekstern lenke)
• Løken-Amsrud, Kristin Ingeleiv; Holmøy, Trygve; Bakke, Søren J. et al. (2012). Vitamin D and disease activity in multiple sclerosis before and during interferon beta treatment. (ekstern lenke)
• Wergeland, Stig; Torkildsen, Øivind; Myhr, Kjell-Morten et al. (2011). Dietary vitamin D3 supplements reduce demyelination in the cuprizone model. (ekstern lenke)

Poster

• Rødal, Linn Elin; Smedal, Tori; Wergeland, Stig et al. (2025). Tidlig screening av blæredysfunksjon ved multippel sklerose - et kvalitetsforbedringsprosjekt. (ekstern lenke)
• Rasmussen, Tilde; König, Marton; Lorentzen, Åslaug Rudjord et al. (2022). Safety of a third SARS CoV 2 mRNA vaccine dose in people with multiple sclerosis. (ekstern lenke)
• König, Marton; Wolf, Asia-Sophia Fumika Michaela; Ravussin, Anthony et al. (2022). Immunogenicity and efficacy of mRNA-COVID-19 vaccines in people with multiple sclerosis. (ekstern lenke)
• König, Marton; Lorentzen, Åslaug Rudjord; Torgauten, Hilde Marie et al. (2021). Humoral Immunity to SARS-CoV-2 mRNA Vaccination in People with Multiple Sclerosis using High-Efficacy Disease Modifying Therapies. (ekstern lenke)
• Fjær, Sveinung; Wergeland, Stig; Bø, Lars (2014). Magnetization transfer ratio (MTR) increased unexpectedly in EAE induced mice.. (ekstern lenke)

Leserinnlegg

• Lie, Ingrid Anne; Rød, Brit Ellen; Stokke, Silje Agnethe et al. (2023). Interferon β1a treatment does not influence serum Epstein-Barr virus antibodies in patients with multiple sclerosis. (ekstern lenke)
• Wergeland, Stig; Riise, Trond; Torkildsen, Øivind (2018). Response to 'Seasonal variation of vitamin D and Epstein?Barr virus antibody in multiple sclerosis patients', a comment letter regarding 'Vitamin D, HLA-DRB1 and Epstein-Barr virus antibody levels in a prospective cohort of multiple sclerosis patients'. (ekstern lenke)

Kronikk

• Torkildsen, Øivind; Rød, Brit Ellen; Bø, Lars et al. (2022). Amming og behandling av multippel sklerose. (ekstern lenke)

Vitenskapelig oversiktsartikkel/review

• Myhr, Kjell-Morten; Grytten, Nina; Torkildsen, Øivind et al. (2015). The Norwegian Multiple Sclerosis Registry and Biobank. (ekstern lenke)
• Stokke, Silje Agnethe; Wergeland, Stig; Torkildsen, Øivind et al. (2013). Neuromyelitis optica. (ekstern lenke)
• Wergeland, Stig; Torkildsen, Øivind; Bø, Lars et al. (2012). Polyunsaturated fatty acids in multiple sclerosis therapy. (ekstern lenke)

Vitenskapelig foredrag

• Røsjø, Egil Rørvik; Myhr, Kjell-Morten; Kampman, Margitta Theodora et al. (2015). Vitamin D og interferon-behandling ved multippel sklerose. (ekstern lenke)

Doktorgradsavhandling

• Wergeland, Stig (2013). Vitamin D and ω-3 polyunsaturated fatty acids as disease modifying factors in multiple sclerosis. (ekstern lenke)

Se en full oversikt over publikasjoner i Cristin